How should methotrexate‑induced acute interstitial pneumonia be managed?

Management of Methotrexate-Induced Acute Interstitial Pneumonitis

Immediately discontinue methotrexate and initiate corticosteroid therapy for suspected methotrexate-induced acute interstitial pneumonitis. This is the cornerstone of management based on FDA labeling and clinical guidelines 1.

Immediate Actions

Drug Cessation

• Stop methotrexate immediately upon suspicion of pneumonitis—do not wait for confirmatory testing 1
• The FDA explicitly warns that methotrexate-induced lung disease "may occur acutely at any time during therapy" and "is not always fully reversible" with fatalities reported 1
• Most cases are reversible on withdrawal, but delayed recognition increases mortality risk 2

Corticosteroid Initiation

• Start prednisone 1-2 mg/kg/day for symptomatic patients 3
• For severe cases (Grade 3-4): methylprednisolone IV 1-2 mg/kg/day 3
• Taper corticosteroids over 4-6 weeks once clinical improvement occurs 3

Important caveat: While corticosteroids are standard practice, some cases resolve spontaneously without steroids 4. However, given the potentially fatal nature and unpredictability of outcomes, withholding corticosteroids is not recommended in clinical practice 5, 6.

Diagnostic Workup

Clinical Presentation to Recognize

• Pulmonary symptoms: dry nonproductive cough, progressive dyspnea, fever 1, 5
• Timing: Can occur at any dose and any time during therapy, though often within first year 2, 5
• Physical findings: hypoxemia, tachypnea, crackles on auscultation 5

Essential Investigations

• Chest imaging: CT chest (preferably with contrast) showing bilateral interstitial or mixed interstitial-alveolar infiltrates, often with lower lobe predominance 3, 5
• Exclude infection aggressively: This is critical as Pneumocystis jirovecii pneumonia (PCP) can mimic methotrexate pneumonitis 1, 7
  • Nasal swab, sputum culture, blood cultures, urine culture 3
  • Consider bronchoalveolar lavage (BAL) with PCR for PCP, especially in patients on biologics 7
  • Poor response to corticosteroids should trigger immediate investigation for PCP 7
• Pulmonary function tests: Restrictive pattern with reduced diffusion capacity 5
• Laboratory: Elevated LDH may suggest PCP rather than drug-induced pneumonitis 7

Diagnostic Criteria

The diagnosis requires 8:

1. Newly identified bilateral nonsegmental pulmonary opacities on imaging
2. Temporal association with methotrexate use
3. Exclusion of other causes (infection, underlying disease progression, other drugs)

Grading and Management Algorithm

Grade 1 (Asymptomatic, <25% lung involvement)

• Hold methotrexate
• Monitor weekly with pulse oximetry and clinical assessment
• Repeat chest imaging in 3-4 weeks
• May resume methotrexate if radiographic improvement documented 3

Grade 2 (Symptomatic, 25-50% lung involvement)

• Hold methotrexate until improvement to Grade 1
• Prednisone 1-2 mg/kg/day, taper over 4-6 weeks 3
• Consider bronchoscopy with BAL and transbronchial biopsy
• Empiric antibiotics if infection cannot be excluded
• Monitor at least weekly; if no improvement after 48-72 hours, escalate to Grade 3 management 3

Grade 3 (Severe, >50% lung involvement, hospitalization required)

• Permanently discontinue methotrexate 3
• Methylprednisolone IV 1-2 mg/kg/day 3
• Supplemental oxygen to maintain PaO₂ >8 kPa and SaO₂ >92% 9
• If no improvement after 48 hours, add immunosuppressive agent: infliximab, mycophenolate mofetil IV, IVIG, or cyclophosphamide 3
• Pulmonary and infectious disease consultations 3

Grade 4 (Life-threatening, intubation required)

• Same as Grade 3 plus intensive care management
• Consider bronchoscopy if patient can tolerate 3

Key Clinical Pitfalls

Distinguishing from PCP

This is the most critical diagnostic challenge 7:

• PCP typically: develops insidiously, elevated LDH, poor response to corticosteroids alone, requires BAL with PCR for diagnosis
• Methotrexate pneumonitis typically: acute/subacute onset, responds to drug withdrawal and corticosteroids
• When in doubt: Treat empirically for both—continue corticosteroids AND add trimethoprim-sulfamethoxazole 7
• Risk is particularly high in patients on TNF inhibitors like adalimumab 7

Distinguishing from RA-ILD

• RA-ILD: chronic course, UIP or NSIP pattern, associated with smoking, male gender, anti-CCP positivity 10
• Methotrexate pneumonitis: acute/subacute, temporal relationship to drug initiation/dose increase 10
• Methotrexate can be continued in stable RA-ILD but should be stopped if pneumonitis suspected 11

Rechallenge Considerations

• Generally contraindicated after Grade 3-4 reactions 3
• Successful rechallenge has been reported in select cases with prophylactic corticosteroids 12
• If rechallenge attempted: use corticosteroid prophylaxis, close monitoring, and only after complete resolution of pneumonitis (typically 2-3 months) 12
• Consider alternative DMARDs (rituximab, abatacept, tocilizumab) rather than rechallenge 10

Monitoring During Methotrexate Therapy

Baseline

• Chest X-ray mandatory before starting methotrexate 2
• Baseline pulmonary function tests in high-risk patients 2

Ongoing

• Educate all patients about pulmonary symptoms and instruct immediate reporting 1, 6
• No routine imaging required in asymptomatic patients
• Investigate any new pulmonary symptoms immediately 1

Prognosis

• Most patients recover with prompt recognition and treatment 5, 6
• Mortality occurs primarily with delayed diagnosis or when infection is missed 1
• Chronic pneumonitis can occur in <2% of cases requiring prolonged corticosteroid taper 3